Navigation Links
Life Sciences Real Estate Outperforming Other Sectors
Date:7/24/2009

Occupancy rates and rents for spaces leased to biotech, pharma and medical devices tenants are faring better in some markets than office, retail and other property sectors.

Minneapolis, MN (Vocus) July 24, 2009 -- There’s no denying that the recession, the credit crunch, pharmaceuticals industry mergers and an overall slump in the commercial property market are having a negative impact on the life sciences real estate sector. In most markets, vacancies are up while absorption and net rental rates are down. But a Page 1 article in the most recent edition of Bioscience Real Estate Insights suggests that the life sciences niche still seems to be holding up better than most other commercial real estate sectors – particularly the “four main food groups” of office, industrial, retail and multifamily.

“There are even some pockets of surprisingly good news,” says Murray W. Wolf, publisher and founding editor of BREI. “Some bio clusters are reporting flat or even increased space absorption, with little or no increase in vacancy rates. And in some markets, like Greater Boston, vacancy rates for lab space have actually declined.”

BREI is a national, business-to-business newsletter that covers bioscience real estate, development financing and investment. BREI was launched in 2006 in recognition that there is a distinct sector of the commercial real estate market specializing in office, research and development (R&D), laboratory, manufacturing, and distribution space owned or leased by pharma, biotech and medical devices companies, as well as colleges, universities, hospitals and other biomedical research institutions.

In addition to the lead story on leasing, the current edition of BREI also includes extensive articles about:

 
  • How the demise of a California biotech firm actually benefited two of its publicly traded REIT landlords
  • The opening of $100 million-plus research facilities in California and Utah
  • Plans to expand a controversial biopark in Massachusetts to more than 1 million square feet of space
  • Ernst & Young’s predictions regarding the future of the bio business, as presented at the BIO 2009 conference
  • More BIO 2009 coverage: Why biotech expert Steve Burrill thinks the industry has changed for good
  • What a leading investment banker told the AURP BioParks 2009 conference about the capital markets
  • Bioscience real estate transactions, projects, economic development, companies and people news from North Carolina, Seattle, New York, Nebraska, Maryland, New Jersey, Oregon, Virginia, Pennsylvania, Massachusetts, California, Minnesota, Wisconsin, Michigan, Kansas, Alaska, New Mexico, Illinois, Oklahoma, Ohio, Florida, Indiana, Missouri, Georgia, Colorado and more.

About Bioscience Real Estate Insights

At Bioscience Real Estate Insights, we define the biosciences – or life sciences, as some call them – as the scientific study of living things. The real estate development, financing and investment issues associated with the pharma, biotech and medical devices sectors are unique, and they deserve our specialized editorial focus. This national, B2B newsletter offers the most comprehensive coverage in the industry. For more information regarding BREI, please visit us at www.breinsights.com.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2677404.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Life Sciences Real Estate Outperforming Other Sectors
(Date:2/10/2016)...  Allergan plc (NYSE: AGN ) a leading ... , Allergan,s CEO and President, will be featured as ... the RBC Capital Markets Healthcare Conference on Tuesday, February ... York Palace Hotel in New York, NY ... can be accessed on Allergan,s Investor Relations web site ...
(Date:2/10/2016)... ... 10, 2016 , ... HOLLOWAY AMERICA, a leading custom stainless ... Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The Rocky ... its annual event, which will run from 3:00 p.m. - 8:30 p.m. at ...
(Date:2/10/2016)... ... 10, 2016 , ... PatientCrossroads announces that the ... online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals since ... which seeks to advance understanding of the hereditary risks for certain kinds of ...
(Date:2/10/2016)... ... February 10, 2016 , ... Cenna Bioscience Inc., an emerging ... of Alzheimer’s disease, announced today it has been selected to present at the Cavendish ... in Palm Beach, Florida. The purpose of the Forum is to help family ...
Breaking Biology Technology:
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
Breaking Biology News(10 mins):